Mares Ltd.    ||    Phone: +49 2571 9588001    ||    Fax: +49 2571 9588003    ||    E-Mail: contact@maresltd.eu

Mesenchymal stem cells are increasingly coming into focus as treatment for vascular  problems/lack of perfusion or for undesirable immunoreactions such as in Graft vs. Host disease (GvhD); another area is in orthopedics, for example, in osteoarthritis (OA).

It is thought that MSCs exert their therapeutic effects by secreting copious quantities of bioactive factors and, consequently, have sometimes been described as pharmaceutical factories transiently present in tissues.  

 

While clear therapeutic effects have been seen in many studies, the level of efficacy sometimes leaves room for improvement and increasing dose sizes may not be feasible. This leaves increasing potency as the best option.

 

We have identified a small molecule which dramatically enhances the efficacy of MSCs. It does so by simple addition to MSCs prior to injection, is not known to be toxic at relevant concentrations and exerts a transient effect.

 

We are looking for partners to co-develop the technology to market-ready level. 

‚Äč

For your ready reference, please see the slide deck linked here:

Contact us